Syngene International Expands Capabilities
Syngene International, a global contract research, development and manufacturing organization, is adding a GMP bioconjugation suite at its commercial biologics facility in Bengaluru.
This new capability will complement its commercial payload, linker, and monoclonal antibodies services, allowing Syngene to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.
Syngene will be among a handful of CDMOs with full-service capabilities.
- Location: Bengaluru, India
- Facility: Commercial biologics facility [Unit 3]
- Services: End-to-end services for antibody-drug conjugates (ADCs)
Author's summary: Syngene International expands ADC capabilities.
More News
- What is canine cognitive dysfunction syndrome? | dvm360
- Lightning place forward Mitchell Chaffee on waivers
- Trump Admin’s Laziness Is Messing Up Its Effort to Deploy the National Guard to Portland
- Court: Federal Agencies Broke Laws in Approving Massive Logging Project in Montana Grizzly Country
- Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age | PharmExec
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Brad Sutton on Boston Scientific's PFA advantage and advice for medtech pros
- FG backs Dangote Refinery’s expansion to 1.4m barrels daily — Lokpobiri